Endometriosis-associated ovarian cancer
https://doi.org/10.17650/1994-4098-2016-12-4-47-51
Abstract
This article reviews recent advance in our understanding of ovarian endometriomas, with special reference of atypical epithelial features (atypical endometriosis) and its relationship to neoplasm. Mainly, two epithelial ovarian carcinoma subtypes, the ovarian clear cell carcinomas and the endometrioid ovarian carcinomas, have been molecularly and epidemiologically linked to endometriosis. The clear cell and endometrioid adenocarcinomas have common immunohistochemical markers, genetic changes are the same as atypical endometriosis. The occurrence of ARID1A mutations and alterations in the PI3K/AKT pathway in endometriosis and endometriosis-associated ovarian carcinomas, as well as the possible functional and clinical implications are discussed in this review. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis associated ovarian cancers and endometrial cancers.
About the Authors
S. A. Levakov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Obstetrics and Gynecology, Institute of Professional Education,
Build. 2, 8 Trubetskaya St., Moscow 119991
T. A. Gromova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Obstetrics and Gynecology, Institute of Professional Education,
Build. 2, 8 Trubetskaya St., Moscow 119991
A. G. Kedrova
Institute for Advanced Training, Federal Biomedical Agency of Russia
Russian Federation
Russian Federation
Department of Obstetrics and Gynecology,
91 Volokolamskoe Shosse, Moscow 125371
N. A. Sheshukova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Obstetrics and Gynecology, Institute of Professional Education,
Build. 2, 8 Trubetskaya St., Moscow 119991
References
1. Kok V.C., Tsai H.J., Su C.F. et al. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer 2015;25:968–76.
2. Mackay H.J., Brady M.F., Oza A.M. et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010;20:945–52.
3. Sampson J.A. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 1925;10:1–72.
4. Ness R.B., Cramer D.W., Goodman M.T. et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2002;155:217–24.
5. Nezhat F. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 2008;90:1559–70.
6. Jiang Q.Y., Wu R.J. Growth mechanisms of endometriotic cells in implanted places: A review. Gynecol Endocrinol 2012;28:562–67.
7. Melin A., Sparen P., Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007;22:3021–6.
8. Machado-Linde F., Sánchez-Ferrer M.L., Cascales P. et al. Prevalence of endometriosis in epithelial ovarian cancer. Analysis of the associated clinical features and study on molecular mechanisms involved in the possible causality. Eur J Gynaecol Oncol 2015;36(1):21–4.
9. Akbarzadeh-Jahromi M., Shekarkhar G., Sari Aslani F. et al. Prevalence of Endometriosis in Malignant Epithelial Ovarian Tumor. Arch Iran Med 2015;18(12):844–8.
10. Köbel M., Bak J., Bertelsen B.I. et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014;64(7):1004–13. DOI: 10.1111/his.12349.
11. Yoshikawa H., Jimbo H., Okada S. et al. Prevalence of Endometriosis in Ovarian Cancer. Gynecol Obstet Invest 2000;50 (Suppl 1):11–7.
12. Higashiura Y., Kajihara H., Shigetomi H. et al. Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett 2012;4:3–9.
13. Jiang Q.Y., Wu R.J. Growth mechanisms of endometriotic cells in implanted places: A review. Gynecol Endocrinol 2012;28:562–7.
14. Zeitoun K., Takayama K., Sasano H. et al. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: Failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 1998;83:4474–80.
15. Iwabuchi T., Yoshimoto C., Shigetomi H. et.al. Cyst fluid hemoglobin species in endometriosis and its malignant transformation: The role of metallobiology. Oncol Lett 2016;11(5):3384–8.
16. Lim M.C., Chun K.C., Shin S.J. et al. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: A multicenter retrospective study. Cancer Epidemiol Biomark Prev 2010;19:398–404.
17. Flores-Alcantar A., Gonzalez-Sandoval A., Escalante-Alcalde D. et al. Dynamics of expression of arid1a and arid1b subunits in mouse embryos and in cells during the cell cycle. Cell Tissue Res 2011;345:137–48.
18. Yamamoto S., Tsuda H., Takano M. et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012;25(4):615–24.
19. Alifrangis C., Thornton A., Fotopoulou C. et al. Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer. Gynecol Oncol Rep 2016;18:42–4.
20. Samartzis E.P., Noske A., Dedes K.J. et al. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci 2013;14(9):18824–49.
21. Tan D.S., Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol 2007;60:355–60.
22. Maeda D., Shih I.M. Pathogenesis and the role of arid1a mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013;20;45–52.
23. Mandai M., Matsumura N., Baba T. et al. Ovarian clear cell carcinoma as a stress- responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 2011;310:129–33.
24. Stamp J.P., Gilks C.B., Wesseling M. et al. BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. Int J Gynecol Cancer 2016;26(5): 825–32.
25. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009;9(8):550–62.
26. Yamamoto S., Tsuda H., Takano M. et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 2011;225:189–94.
27. Guan B., Wang T.L., Shih I.M. In ARID1A loss in collaboration with PI3K- pathway activation leads to ovarian tumorigenesis in mouse. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, 6–10 April 2013; Walter E., ed.; AACR: Philadelphia, PA, USA, 2013; LB-259.
28. Stamp J.P., Gilks C.B., Wesseling M. et al. B AF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. Int J Gynecol Cancer 2016;26(5): 825–32.
29. Tanase Y., Furukawa N., Kobayashi H. et al. Malignant transformation from endometriosis to atypical endometriosis and finally to endometrioid adenocarcinoma within 10 years. Case Rep Oncol 2013;6:480–4.
30. Grandi G., Toss A., Cortesi L. et al. The association between endometriomas and ovarian cancer: preventive effect of inhibiting ovulation and menstruation during reproductive life. BioMed Res Int 2017. PMID: 26413541.
Review
For citations:
Levakov S.A., Gromova T.A., Kedrova A.G., Sheshukova N.A. Endometriosis-associated ovarian cancer. Tumors of female reproductive system. 2016;12(4):47-51. (In Russ.) https://doi.org/10.17650/1994-4098-2016-12-4-47-51
Views:
789
Email this article 